26 research outputs found
Forest plot for rs16969968 C vs T allele.
<p>Forest plot for rs16969968 C vs T allele.</p
Pooled ORs with 95%CIs for multiple variable adjustment.
a<p>: Heterozygote inheritance model (CT vs CC genotype); <sup>b</sup>: Homozygote inheritance model (CC vs TT genotype).</p
Forest plot for rs1051730 T vs C.
<p>The fixed effect model was used in both overall and subgroup analyses. Each box represents the OR point estimate, and its area is proportional to the weight of the study. Diamond and broken lines represent the overall estimate, with 95%CI represented by the width. The solid vertical line is set at the null value (OR = 1.0).</p
ORs with 95%CIs for heterozygote and homozygote genotypes of each SNP.
<p>ORs with 95%CIs for heterozygote and homozygote genotypes of each SNP.</p
Publication bias in meta-analyses for each inheritance model.
<p>Publication bias in meta-analyses for each inheritance model.</p
Sensitivity analysis for the rs1051730 heterozygote genotype (CT vs CC).
<p>Sensitivity analysis for the rs1051730 heterozygote genotype (CT vs CC).</p
Metabolomic Study on Iohexol-Induced Nephrotoxicity in Rats Based on NMR and LC–MS Analyses
Iohexol,
the raw material of nonionic X-ray computed tomography
(X-CT) contrast medium, is usually injected into the vein before CT
angiography diagnosis. It is used for angiography, urography, and
lymphography. With the advantages of low contrast density and good
tolerance, it is currently one of the most popular contrast media.
However, the renal toxicity of iohexol seriously affects its safety
use. Therefore, it is of great importance to identify new potential
diagnostic biomarkers and therapeutic targets in the process of contrast
medium-induced acute kidney injury (CI-AKI) in order to safely use
iohexol in clinical practice. In this study, in order to understand
the metabolic mechanism of CI-AKI, ultra-high-performance liquid chromatography/quadrupole-Orbitrap-mass
spectrometry and 1H NMR-based metabolomic techniques were
utilized to study the metabolic spectra of kidney, plasma, and urine
from CI-AKI rats, and a total of 30 metabolites that were closely
related to kidney injury were screened out, which were mainly related
to 9 metabolic pathways. The results further indicated that iohexol
might intensify kidney dysfunction in vivo by disrupting
the metabolic pathways in the body, especially through blocking energy
metabolism, amino acid metabolism, and promoting inflammatory reactions
